Zhong Xiaoqing, Di Zhenning, Xu Yuanxin, Liang Qifan, Feng Kuanhan, Zhang Yuting, Di Liuqing, Wang Ruoning
College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jiangsu Provincial TCM Engineering Technology Research Center of High Efficient Drug Delivery System, Nanjing, 210023, China.
Chin Med. 2022 Feb 10;17(1):21. doi: 10.1186/s13020-022-00577-9.
Mineral drugs are an important constituent of traditional Chinese medicine (TCM). Taking minerals that contain heavy metals as drugs is a very national characteristic part of TCM. However, the safety and scientific nature of mineral drugs are controversial owing to their heavy metals and strong toxicity. In 2000, the Food and Drug Administration (FDA) authorized arsenic trioxide (ATO) as first-line therapy for acute promyelocytic leukemia. This makes the development and utilization of mineral drugs become a research hotspot. The development of nanomedicine has found a great prospect of mineral drugs in nano-delivery carriers. And that will hold promise to address the numerous biological barriers facing mineral drug formulations. However, the studies on mineral drugs in the delivery system are few at present. There is also a lack of a detailed description of mineral drug delivery systems. In this review, the advanced strategies of mineral drug delivery systems in tumor therapy are summarized. In addition, the therapeutic advantages and research progress of novel mineral drug delivery systems are also discussed. Here, we hope that this will provide a useful reference for the design and application of new mineral drug delivery systems.
矿物药是中药的重要组成部分。将含重金属的矿物入药是中药极具民族特色的一部分。然而,由于矿物药含有重金属且毒性较强,其安全性和科学性存在争议。2000年,美国食品药品监督管理局(FDA)批准三氧化二砷(ATO)作为急性早幼粒细胞白血病的一线治疗药物。这使得矿物药的开发利用成为研究热点。纳米医学的发展为矿物药在纳米递送载体方面找到了广阔前景。这有望解决矿物药制剂面临的众多生物屏障问题。然而,目前关于矿物药在递送系统方面的研究较少。对矿物药递送系统也缺乏详细描述。在本综述中,总结了矿物药递送系统在肿瘤治疗中的先进策略。此外,还讨论了新型矿物药递送系统的治疗优势和研究进展。在此,我们希望这能为新型矿物药递送系统的设计和应用提供有益参考。